237 related articles for article (PubMed ID: 26039708)
1. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
4. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
[TBL] [Abstract][Full Text] [Related]
7. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
10. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism.
Yeung KS; Tso WWY; Ip JJK; Mak CCY; Leung GKC; Tsang MHY; Ying D; Pei SLC; Lee SL; Yang W; Chung BH
Mol Autism; 2017; 8():66. PubMed ID: 29296277
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
[TBL] [Abstract][Full Text] [Related]
13. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Agell L; Hernández S; Salido M; de Muga S; Juanpere N; Arumí-Uria M; Menendez S; Lorenzo M; Lorente JA; Serrano S; Lloreta J
Mod Pathol; 2011 Mar; 24(3):443-52. PubMed ID: 21113138
[TBL] [Abstract][Full Text] [Related]
14.
Amato O; Buisseret L; Gebhart G; Plouznikoff N; Larsimont D; Awada A; Piccart M; Aftimos P
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36863843
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract][Full Text] [Related]
20. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]